Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women

Background: Recent data suggest that statins used in the treatment of hypercholesterolaemia decrease fracture risk. In this study, we aimed to investigate prospectively whether statins have an additive effect to bisphosphonates (risedronate) according to the primary hypothesis that the addition of atorvastatin to risedronate would produce an increase, from baseline, in lumbar vertebrae and total hip BMD that was greater than that observed with risedronate alone. Methods: A total of 120 hypercholesterolaemic postmenopausal women with osteoporosis or osteopenia were randomized to receive risedronate (5 mg/day) or risedronate (5 mg/day) plus atorvastatin (20 mg/day). Changes in bone mineral density in the lumbar spine and hip, and serum lipid and glucose metabolism changes were assessed. Results: Compared with risedronate alone, at 6 months, risedronate plus atorvastatin produced significantly greater increases in the bone mineral density of the lumbar spine (1.58% versus 0.75%, p < 0.05). We found no difference after therapy in BMD of the total hip (1.2% versus 1.1%). Risedronate plus atorvastatin therapy had favorable effects on the serum lipid profile: LDL and total cholesterol. Serum fasting glucose and HbA1c levels were not affected during the treatments. Conclusion: Statins have modest additive effects to bisphosphonates in improving lumbar spine bone mineral density in hypercholesterolaemic postmenopausal women with established osteoporosis-osteopenia. A long-term study with adequate sample size is necessary to assess the effects of statins - in combination or alone - on the bones and prevention of fractures. © 2004 Elsevier Ireland Ltd. All rights reserved.

Dergi Adı European Journal of Obstetrics and Gynecology and Reproductive Biology
Dergi Cilt Bilgisi 120
Dergi Sayısı 1
Sayfalar 63 - 68
Yayın Yılı 2005
Eser Adı
[dc.title]
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women
Yazar
[dc.contributor.author]
Tanriverdi H.A.
Yazar
[dc.contributor.author]
Barut A.
Yazar
[dc.contributor.author]
Sarikaya S.
Yayın Yılı
[dc.date.issued]
2005
Yayıncı
[dc.publisher]
Elsevier Ireland Ltd
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: Recent data suggest that statins used in the treatment of hypercholesterolaemia decrease fracture risk. In this study, we aimed to investigate prospectively whether statins have an additive effect to bisphosphonates (risedronate) according to the primary hypothesis that the addition of atorvastatin to risedronate would produce an increase, from baseline, in lumbar vertebrae and total hip BMD that was greater than that observed with risedronate alone. Methods: A total of 120 hypercholesterolaemic postmenopausal women with osteoporosis or osteopenia were randomized to receive risedronate (5 mg/day) or risedronate (5 mg/day) plus atorvastatin (20 mg/day). Changes in bone mineral density in the lumbar spine and hip, and serum lipid and glucose metabolism changes were assessed. Results: Compared with risedronate alone, at 6 months, risedronate plus atorvastatin produced significantly greater increases in the bone mineral density of the lumbar spine (1.58% versus 0.75%, p < 0.05). We found no difference after therapy in BMD of the total hip (1.2% versus 1.1%). Risedronate plus atorvastatin therapy had favorable effects on the serum lipid profile: LDL and total cholesterol. Serum fasting glucose and HbA1c levels were not affected during the treatments. Conclusion: Statins have modest additive effects to bisphosphonates in improving lumbar spine bone mineral density in hypercholesterolaemic postmenopausal women with established osteoporosis-osteopenia. A long-term study with adequate sample size is necessary to assess the effects of statins - in combination or alone - on the bones and prevention of fractures. © 2004 Elsevier Ireland Ltd. All rights reserved.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Atorvastatin
Konu Başlıkları
[dc.subject]
Bone mineral density
Konu Başlıkları
[dc.subject]
Hypercholesterolaemia
Konu Başlıkları
[dc.subject]
Osteoporosis
Konu Başlıkları
[dc.subject]
Postmenopause
Konu Başlıkları
[dc.subject]
Risedronate
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0301-2115
İlk Sayfa Sayısı
[dc.identifier.startpage]
63
Son Sayfa Sayısı
[dc.identifier.endpage]
68
Dergi Adı
[dc.relation.journal]
European Journal of Obstetrics and Gynecology and Reproductive Biology
Dergi Sayısı
[dc.identifier.issue]
1
Dergi Cilt Bilgisi
[dc.identifier.volume]
120
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.ejogrb.2004.08.007
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/7633
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
29
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
04 Şubat 2024 15:29
Google Kontrol
Tıklayınız
risedronate lumbar atorvastatin mg/day) effects mineral density statins therapy versus greater hypercholesterolaemic glucose postmenopausal additive bisphosphonates prevention fractures Elsevier Ireland favorable Statins difference rights reserved Risedronate necessary combination levels treatments modest during improving established osteoporosis-osteopenia
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms